Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 15;11(2):217-250.
doi: 10.1007/s13167-020-00203-4. eCollection 2020 Jun.

Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies

Vamsi Reddy #  1 , Dayton Grogan #  1 , Meenakshi Ahluwalia  2 , Évila Lopes Salles  3 , Pankaj Ahluwalia  2 , Hesam Khodadadi  3 , Katelyn Alverson  1 , Andy Nguyen  1 , Srikrishnan P Raju  1   4 , Pankaj Gaur  5   6 , Molly Braun  1   7   8 , Fernando L Vale  1 , Vincenzo Costigliola  9 , Krishnan Dhandapani  1 , Babak Baban  3 , Kumar Vaibhav  1
Affiliations
Review

Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies

Vamsi Reddy et al. EPMA J. .

Abstract

Cannabis-inspired medical products are garnering increasing attention from the scientific community, general public, and health policy makers. A plethora of scientific literature demonstrates intricate engagement of the endocannabinoid system with human immunology, psychology, developmental processes, neuronal plasticity, signal transduction, and metabolic regulation. Despite the therapeutic potential, the adverse psychoactive effects and historical stigma, cannabinoids have limited widespread clinical application. Therefore, it is plausible to weigh carefully the beneficial effects of cannabinoids against the potential adverse impacts for every individual. This is where the concept of "personalized medicine" as a promising approach for disease prediction and prevention may take into the account. The goal of this review is to provide an outline of the endocannabinoid system, including endocannabinoid metabolizing pathways, and will progress to a more in-depth discussion of the therapeutic interventions by endocannabinoids in various neurological disorders.

Keywords: 2-Arachidonyl glycerol; Alzheimer’s disease; Amyloid lateral sclerosis; Anandamide; Anxiety; Cancer; Cannabinoid receptor; Depression; Disease management; Endocannabinoid system; Epilepsy; Health policy; Huntington’s disease; Multi-professional expertise; Multiple sclerosis; Neurological disorder; Pain; Parkinson’s disease; Predictive preventive personalized medicine (PPPM); Schizophrenia; Stroke; Therapeutic strategies; Traumatic brain injury.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
The endocannabinoid system in normal cellular homeostasis and its dysregulation in different neuropathologies. Schematic diagram shows ECS and its different components in normal cellular physiology. The dysregulated ECS as result of injury or pathologies to brain, becomes inefficient to maintain cellular homeostasis, and exaggerates the progression of different neurological disorders
See this image and copyright information in PMC

References

    1. Badowski ME. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol. 2017;80(3):441–449. - PMC - PubMed
    1. Rock EM, Parker LA. Cannabinoids as potential treatment for chemotherapy-induced nausea and vomiting. Front Pharmacol. 2016;7:221. - PMC - PubMed
    1. Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–480. - PMC - PubMed
    1. Feigin VL, Vos T. Global burden of neurological disorders: from global burden of disease estimates to actions. Neuroepidemiology. 2019;52(1–2):1–2. - PubMed
    1. WHO. Global burden of neurological disorders: estimates and projections. In: Neurological disorders: public health challenges. Geneva, Switzerland: WHO Press. https://www.who.int/mental_health/neurology/chapter_2_neuro_disorders_pu.... Accessed Jan 22 2020.

LinkOut - more resources